1801 — Innovent Biologics Share News
0.000.00%
Last trade - 00:00- HK$150.85bn
- HK$130.09bn
- CNY13.04bn
China's Innovent jump most in nearly a year on Pfizer cancer drug deal
Brief: Innovent Biologics Enters Global Strategic Collaboration With Pfizer For 12 Oncology Programs
Innovent Biologics, Pfizer strike $10.5 bln cancer drug deal amid China biotech boom (updated)
China's Innovent Biologics, Pfizer strike up to $10.5 billion cancer drug deal
Brief: Pfizer And Innovent Biologics Enter Global Strategic Collaboration To Accelerate Development Of Innovative Oncology Medicines
Brief: Innovent Biologics Says China's NMPA Approves Tyvyt And Elunate Combination For Advanced Renal Cell Carcinoma
Innovent Biologics set for biggest rise in 2 weeks on robust Q1 revenue growth
Brief: Innovent Biologics Posts Q1 2026 Total Product Revenue Over RMB3.8 Billion
Factbox: Race to launch weight-loss pill heats up as Lilly wins US approval
Innovent Biologics set for biggest jump in 5 months on FY revenue growth
Brief: Innovent Biologics Posts FY Profit RMB813.6 Million
Brief: Innovent Biologics Says FY IFRS Revenue Rmb13.04 Billion
Brief: Innovent Biologics Says Obtained Early Clearance From Federal Trade Commission
Factbox: Top pharma companies racing to launch a weight-loss pill
Brief: Innovent Biologics Says Jaypirca Received Approval By NMPA China
Chinese biotech aims to finish trials by 2028 for spray with Wegovy active ingredient (updated)
China biotech aims to finish trials by 2028 for spray with Wegovy active ingredient
Press Digest: Wall Street Journal - February 9
Innovent Biologics jumps most in five months on Eli Lilly deal